Twist Bioscience (TWST) Total Non-Current Liabilities (2018 - 2026)

Twist Bioscience (TWST) has reported Total Non-Current Liabilities for 9 consecutive years, with $220.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Non-Current Liabilities rose 42.13% year-over-year to $220.4 million; the TTM figure through Mar 2026 stood at $220.4 million (up 42.13% YoY), while the FY2025 annual figure was $168.2 million, up 19.07% from the prior year.
• Total Non-Current Liabilities advanced to $220.4 million in Q1 2026 per TWST's latest filing, from $181.2 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $220.4 million in Q1 2026 and bottomed at $141.2 million in Q3 2024.
• Historically, Total Non-Current Liabilities has averaged $159.5 million across 5 years, with a median of $152.7 million in 2023.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities surged 1296.67% — and 2023, when it fell 13.01%.
• Twist Bioscience's Total Non-Current Liabilities stood at $163.6 million in 2022, then declined by 13.01% to $142.3 million in 2023, then grew by 6.98% to $152.2 million in 2024, then rose by 19.06% to $181.2 million in 2025, then increased by 21.59% to $220.4 million in 2026.
• Business Quant data shows TWST's Total Non-Current Liabilities at $220.4 million in Q1 2026, $181.2 million in Q4 2025, and $168.2 million in Q3 2025.